Search
Novavax Inc
NVAXAdd to Watchlist
7.320USD
-0.120-1.61%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
More Details of Novavax Inc Company
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Novavax Inc Info
Ticker SymbolNVAX
Company nameNovavax Inc
IPO dateMay 16, 1973
CEOJacobs (John C)
Number of employees952
Security typeOrdinary Share
Fiscal year-endMay 16
Address21 Firstfield Rd
CityGAITHERSBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20878
Phone12402682000
Websitehttps://www.novavax.com/?locale=US
Ticker SymbolNVAX
IPO dateMay 16, 1973
CEOJacobs (John C)
Company Executives of Novavax Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.56K
--
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
134.64K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
98.65K
+19.14%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
92.10K
+20.50%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
90.07K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
66.25K
+28.50%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
62.95K
+29.99%
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
23.56K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.56K
--
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
134.64K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
98.65K
+19.14%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
92.10K
+20.50%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
90.07K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
66.25K
+28.50%
FAQs
Who are the top five shareholders of Novavax Inc?
The top five shareholders of Novavax Inc are: Mr. John C. Jacobs
How many institutions hold shares of Novavax Inc (NVAX)?
As of 2026Q1, 557 institutions hold shares of Novavax Inc, with a combined market value of approximately 128.09M, accounting for 77.98% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 7284856.00.
What is the biggest source of revenue for Novavax Inc?
In 2026Q1, the Product business generated the highest revenue for Novavax Inc, amounting to 685.04M and accounting for 60.97% of total revenue.